期刊文献+

胃肠道间质瘤临床病理分析 被引量:1

下载PDF
导出
摘要 目的:探讨胃肠道间质瘤(GIST)的临床病理特征、免疫组化特点及鉴别诊断。方法:分析22例GIST的组织学形态,并行免疫组化标记及结合相关文献进行讨论。结果:瘤细胞多为梭形细胞,本组占21例,常见形态学构象有编织状、束状、漩涡状、栅栏状等;其中1例肿瘤细胞呈现出上皮样结构。免疫组化CD117均阳性,CD34阳性率为86.4%,DOG1阳性率为81.8%。Desmin、α-SMA、CK均阴性。结论:GIST病理学诊断,需结合组织学形态及免疫组化标记结果,CD117、CD34、DOG1标记阳性是确诊GIST的可靠依据,必要时需要进行相关突变基因检测。
作者 张坤 白石
出处 《医学理论与实践》 2016年第23期3267-3268,共2页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献6

二级参考文献97

  • 1石素胜,孙耘田,白月奎,邵永孚.胃肠道间质瘤多因素预后分析[J].诊断病理学杂志,2006,13(1):21-25. 被引量:15
  • 2王林,李海刚,曾韵洁,曾弘,沈溪明.胃肠道间质瘤43例临床病理及免疫组化特点[J].中华肿瘤防治杂志,2006,13(5):375-377. 被引量:6
  • 3贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 4Li J,Gong FJ,Shen L,et al.Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour[J].Euro J Sur Oncol,2011,37(4):319-324.
  • 5Corless CL,Ballman KV,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):Results of the intergroup phase Ⅲ trial ACOSOG Z9001[J].J Clin Oncol,2010,28 (15 Suppl):a10006.
  • 6Joensuu H,Eriksson M,Hartmann J,et al.Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence:final results of a randomized trial (SSGXⅧ/AIO)[J].J Clin Oncol,2011,29(Suppl):aLBAI.
  • 7DeMatteo RP,Owzar K,Antonescu CR,et al.Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor (GIST) at high risk of recurrence:The U.S.Intergroup phase Ⅱ trial ACOSOG Z9000[C/OL].2011[2011-07-29].http://www.anco.org/ascov2/Meetings/Abstracts? &vmview = abst-detail-view&confID =53&abstractID = 10450.
  • 8Demetri GD,von Meherm M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
  • 9Zalcberg JR,Verweij J,Casali PG,et al.Outcome of patients with advanced gastrointestinal stromal tumours croasing over to a daily imatinib dose of 800 mg after progression on 400 mg[J].Eur J Cancer,2005,41 (12):1751-1757.
  • 10Rios M,Lecesne A,Bui B,et al.Interruption of imatinib (IM)in GIST patients with advanced disease after one year of treatment:Updated results of the prospective French Sarcoma Group randomized phase Ⅲ trial on long term survival[J].J Clin Oncol,2007,25(18 Suppl):10016.

共引文献155

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部